Phase 3 N=60 Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Cystinosis
Primary: Number of Participants With Treatment-emergent Adverse Events — 58; 37; 24; 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=986 Open Label Study of Long Term Safety Evaluation of Alirocumab
Hypercholesterolemia
Primary: Percentage of Participants Who Experienced Adverse Events (AEs) — 83.9; 87.3; 86.2; 20.6 percentage of participants
Phase 4 N=102 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Multiple Sclerosis
Primary: Percentage of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the GSRS From Day 0 to Day 10 — 17; 33 percentage of…
N/A N=15 A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression
Mood Disorder · Bipolar Disorder · Major Depression
Primary: Hamilton Rating Scale for Depression (HAM-D) — 18.4; 13.4; 12.4; 13.7 units on a scale
Phase 3 N=50 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Adverse Events (AEs) and Serious AEs — 100.0; 54.0 percentage of participants
N/A N=37 The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People
Obesity
Primary: Time to Dinner Request — 158; 150; 140 minutes
Phase 1 N=49 A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
Hypercholesterolemia · Dyslipidemias · Hyperlipidemias
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-04950615 — 65810; 15900; 8922; 10470 nanogram per milliliter (ng/mL)
N/A N=62 Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
Epilepsy · Seizures
Primary: Percent Patients Reaching the Defined Target Dose — 18; 9; 12 Participants
Phase 2 N=65 Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Impetigo · Secondarily Infected Traumatic Lesions
Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants
N/A N=943 Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Participants With Febrile Neutropenia — 3.3; 1.9; 0.4; 0.5 percentage of participants
Phase 3 N=125 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Acromegaly
Primary: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period — 57.9 percentage of subjects…
Phase 2 N=39 Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants
Phase 1 N=13 [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
Alzheimer's Disease · Amnestic Mild Cognitive Impairment
Primary: Number of Participants With Adverse Events (AEs) — 1; 3; 2 Participants
N/A N=338 An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival Stratified by Rash — 9.9288; 8.6795 months — p=0.2361
Phase 3 N=20 Saizen® E-Device User Trial
Growth Disorders
Primary: Subjects' Overall Impression After Using E-Device — 0; 7; 13 subjects